This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Inhibition of proprotein convertase SKI-1 prevents blood vessel alteration after stroke.
Nature cardiovascular research · 2025
Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites.
Alzheimer's & dementia (New York, N. Y.) · 2022
Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
The American journal of the medical sciences · 2020
Latest funding
- $100,000
Development of TRPM2 Inhibitors for the Treatment of Rett Syndrome
CIHR · 2026 · Nominated PI
- $845,324
Preclinical Development of CMD-0001048: A First-in-Class PINK1 Inhibitor Targeting Leukemia Stem Cells in Acute Myeloid Leukemia
CIHR · 2025 · Co-investigator
- $868,275
Uncovering a Novel Neuroprotective Signaling Pathway in Retina
CIHR · 2025 · Co-investigator
4 publications.
Inhibition of proprotein convertase SKI-1 prevents blood vessel alteration after stroke.
Shabanzadeh AP, Ringuette D, Syonov M, Wu Q, Tassew NG, Mun EK, Meek A, Lively S, Suntharalingham SE, Mojica M, Olijnyk L, Qiang B, Foltz WD, Reed M, Moya I, Brown C, Feng J, Qin X, Akula PS, Wälchli T, Carlen PL, Alcaide-Leon P, Monnier PP
Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites.
Meier-Stephenson FS, Meier-Stephenson VC, Carter MD, Meek AR, Wang Y, Pan L, Chen Q, Jacobo S, Wu F, Lu E, Simms GA, Fisher L, McGrath AJ, Fermo V, Barden CJ, Clair HDS, Galloway TN, Yadav A, Campágna-Slater V, Hadden M, Reed M, Taylor M, Kelly B, Diez-Cecilia E, Kolaj I, Santos C, Liyanage I, Sweeting B, Stafford P, Boudreau R, Reid GA, Noyce RS, Stevens L, Staniszewski A, Zhang H, Murty MRVS, Lemaire P, Chardonnet S, Richardson CD, Gabelica V, DePauw E, Brown R, Darvesh S, Arancio O, Weaver DF
Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
Brennecke A, Villar L, Wang Z, Doyle LM, Meek A, Reed M, Barden C, Weaver DF
Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.
Wang Z, Wang Y, Vilekar P, Yang SP, Gupta M, Oh MI, Meek A, Doyle L, Villar L, Brennecke A, Liyanage I, Reed M, Barden C, Weaver DF
Development of TRPM2 Inhibitors for the Treatment of Rett Syndrome
Principal investigators: Reed, Mark A
Keywords: Alzheimer'S Disease; Commercialization; Drug Discovery; Inhibitors; Neurological Disorders; Rett Syndrome; Small Molecule
Preclinical Development of CMD-0001048: A First-in-Class PINK1 Inhibitor Targeting Leukemia Stem Cells in Acute Myeloid Leukemia
Principal investigators: Chan, Steven M
Keywords: Acute Myeloid Leukemia; Cell Cycle Arrest; Drug Development; Leukemia Stem Cells; Mitochondria; Mitophagy; Pink1; Small Molecular Inhibitor
Uncovering a Novel Neuroprotective Signaling Pathway in Retina
Principal investigators: Sivak, Jeremy M
Keywords: Glaucoma; Lipid Mediators; Neurodegeneration; Neuroprotection; Retina
The characterization and therapeutic targeting of aberrant metabolic and inflammatory signaling in chronic lymphedema
Principal investigators: Liu, Fei-Fei
Keywords: Inflammation; Lymphedema; Metabolism; Pharmacogenomics; Therapeutics; Treatment-Related Side Effects
The characterization and therapeutic targeting of metabolic and inflammatory signaling in chronic lymphedema
Principal investigators: Liu, Fei-Fei
Keywords: Inflammation; Lymphedema; Metabolism; Pharmacogenomics; Therapeutics; Treatment-Related Side Effects
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Human Communication Disorders
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.